|
2024 Conference Publication A phase 2 study of de-escalation in resectable, locally advanced cutaneous squamous cell carcinoma (cSCC) with the use of neoadjuvant pembrolizumab: De-SquamateLadwa, Rahul, Lee, Jenny H.J., Porceddu, Sandro V., McGrath, Margaret Louise, Cooper, Caroline, Liu, Howard, Gupta, Ruta, Cuscaden, Claire, Nottage, Michelle K., Clark, Jonathan, Le, Dieu, Pauley, Marketa, Gonzalez-Cruz, Jazmina, Frazer, Ian, Hughes, Brett Gordon Maxwell and Panizza, Benedict J. (2024). A phase 2 study of de-escalation in resectable, locally advanced cutaneous squamous cell carcinoma (cSCC) with the use of neoadjuvant pembrolizumab: De-Squamate. 2024 ASCO Annual Meeting, Chicago, IL United States, 31 May - 4 June 2024. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2024.42.16_suppl.9514 |
|
2024 Conference Publication Defining PD-1/PD-L1 receptor-ligand interactions in the head and neck cancer tumor microenvironment identifies unique ‘immune cell rivers’ of cellular interactionsSadeghirad, Habib, Naei, Vahid Yaghoubi, Monkman, James, Basu, Subham, Wicher, Agata, Ladwa, Rahul, Hughes, Brett G.M. and Kulasinghe, Arutha (2024). Defining PD-1/PD-L1 receptor-ligand interactions in the head and neck cancer tumor microenvironment identifies unique ‘immune cell rivers’ of cellular interactions. American Association for Cancer Research Annual Meeting 2024, San Diego, CA United States, 5-10 April 2024. Philadelphia, PA United States: American Association for Cancer Research. doi: 10.1158/1538-7445.am2024-5188 |
|
2024 Conference Publication Spatial profiling of the tumor microenvironment in head and neck squamous cell carcinoma revealed immune cell type infiltration into the TME as a predictor of immunotherapy responseSadeghirad, Habib, Tan, Chin Wee, Liu, Ning, Monkman, James, Cooper, Caroline, O’Byrne, Ken, Davis, Melissa, Hughes, Brett and Kulasinghe, Arutha (2024). Spatial profiling of the tumor microenvironment in head and neck squamous cell carcinoma revealed immune cell type infiltration into the TME as a predictor of immunotherapy response. American Association for Cancer Research Annual Meeting 2024, San Diego, CA United States, 5-10 April 2024. Philadelphia, PA United States: American Association for Cancer Research. doi: 10.1158/1538-7445.am2024-1154 |
|
2023 Conference Publication Intracranial efficacy of sotorasib versus docetaxel in pretreated KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC): Practice-informing data from a global, phase 3, randomized, controlled trial (RCT)Dingemans, Anne-Marie C., Syrigos, Konstantinos, Livi, Lorenzo, Paulus, Astrid, Kim, Sang-We, Chen, Yuanbin, Felip, Enriqueta, Griesinger, Frank, Ohashi, Kadoaki, Zalcman, Gerard, Hughes, Brett Gordon Maxwell, Sorensen, Jens Benn, Blais, Normand, Ferreira, Carlos G. M., Lindsay, Colin R, Dziadziuszko, Rafal, Ward, Patrick J., Obiozor, Cynthia Chinedu, Wang, Yang and Peters, Solange (2023). Intracranial efficacy of sotorasib versus docetaxel in pretreated KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC): Practice-informing data from a global, phase 3, randomized, controlled trial (RCT). 2023 ASCO Annual Meeting, Chicago, IL United States, 2-6 June 2023. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2023.41.17_suppl.lba9016 |
|
2023 Conference Publication Durvalumab with chemotherapy as first line treatment in advanced pleural mesothelioma: A phase 3, randomised trial (DREAM3R)Forde, Patrick M., Nowak, Anna K., Hughes, Brett Gordon Maxwell, Kok, Peey Sei, Brown, Chris, Sun, Zhuoxin, Anagnostou, Valsamo, O'Byrne, Ken, Yip, Sonia, Cook, Alistair, Lesterhuis, Willem Joost, Pavlakis, Nick, Brahmer, Julie R., Kindler, Hedy L., Tsao, Anne S., Zauderer, Marjorie Glass, Ramalingam, Suresh S. and Stockler, Martin R. (2023). Durvalumab with chemotherapy as first line treatment in advanced pleural mesothelioma: A phase 3, randomised trial (DREAM3R). 2023 ASCO Annual Meeting, Chicago, IL United States, 2-6 June 2023. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2023.41.16_suppl.tps8599 |
|
2023 Conference Publication Spatial phenotyping of cytokine signatures reflecting the immunotherapy responses in head and neck cancerJi, HaYeun, Jhaveri, Niyati, Pratapa, Aditya, Ma, Ning, Ben Cheikh, Bassem, Monkman, James, O’Byrne, Ken, Hughes, Brett, Kulasinghe, Arutha and Braubach, Oliver (2023). Spatial phenotyping of cytokine signatures reflecting the immunotherapy responses in head and neck cancer. Immunology 2023™ Meeting, Washington, DC United States, 11-15 May 2023. Rockville, MD United States: American Association of Immunologists. doi: 10.4049/jimmunol.210.supp.171.09 |
|
2023 Conference Publication Abstract 4626: Spatial profiling of the tumor microenvironment in head and neck cancer identifies immune checkpoints and proteins involved in cell death signaling biomarkers of immunotherapy responseSadeghirad, Habib, Liu, Ning, Monkman, James, Tan, Chin Wee, Cooper, Caroline, Caldera, Jeni, Church, Sarah, Schneider, Fabian, Mansfield, James Robert, O'Byrne, Ken, Davis, Melissa, Hughes, Brett and Kulasinghe, Arutha (2023). Abstract 4626: Spatial profiling of the tumor microenvironment in head and neck cancer identifies immune checkpoints and proteins involved in cell death signaling biomarkers of immunotherapy response. AACR Annual Meeting 2023, Orlando, FL United States, 14-19 April 2023. Philadelphia, PA United States: American Association for Cancer Research. doi: 10.1158/1538-7445.am2023-4626 |
|
2023 Conference Publication Abstract 5647: Single cell, multiomic spatial phenotyping of immunotherapy responses in head and neck cancerJi, HaYeun, Jhaveri, Niyati, Ma, Ning, Cheikh, Bassem B., Pratapa, Aditya, Monkman, James, O’Byrne, Ken, Hughes, Brett, Kulasinghe, Arutha and Braubach, Oliver (2023). Abstract 5647: Single cell, multiomic spatial phenotyping of immunotherapy responses in head and neck cancer. AACR Annual Meeting 2023, Orlando, FL United States, 14-19 April 2023. Philadelphia, PA United States: American Association for Cancer Research. doi: 10.1158/1538-7445.am2023-5647 |
|
2022 Conference Publication The role of thoracic radiotherapy (TRT) in the era of chemoimmunotherapy for extensive stage small cell lung cancer (ES-SCLC)Turner, Cassie L., Prasetio, Tito E., O'Berine, Shannon, Anderson, Georgina, Hughes, Brett G. M., Vignarajah, Dinesh, Castelli, Joanne, Lwin, Zarnie, Houston, Kathleen and Chan, Bryan A. (2022). The role of thoracic radiotherapy (TRT) in the era of chemoimmunotherapy for extensive stage small cell lung cancer (ES-SCLC). HOBOKEN: WILEY. |
|
2022 Conference Publication High-plex spatial proteomic profiling of immunotherapy response groups in head and neck cancer identifies tissue signatures associated with therapy responseKulasinghe, Arutha, Sadeghirad, Habib, Liu, Ning, Monkman, James, Tan, Chin Wee, Cooper, Caroline, Church, Sarah, Schneider, Fabian, Thaagard, Jeppe, Mansfield, James, O’byrne, Kenneth, Davis, Melissa and Hughes, Brett (2022). High-plex spatial proteomic profiling of immunotherapy response groups in head and neck cancer identifies tissue signatures associated with therapy response. SITC 37th Annual Meeting (SITC 2022), Boston, MA United States, 8–12 November 2022. London, United Kingdom: BMJ Group. doi: 10.1136/jitc-2022-sitc2022.0117 |
|
2021 Conference Publication Phase 2 study of pembrolizumab (pembro) for locally advanced (LA) or recurrent/metastatic (R/M) cutaneous squamous cell carcinoma (cSCC): KEYNOTE-629Hughes, Brett G. M., Munoz-Couselo, Eva, Mortier, Laurent, Bratland, Ase, Gutzmer, Ralf, Roshdy, Osama, Gonzalez Mendoza, Rene, Schachter, Jacob, Arance, Ana, Grange, Florent, Meyer, Nicolas, Joshi, Abhishek, Billan, Salem, Zhang, Pingye, Gumuscu, Burak, Swaby, Ramona F. and Grob, Jean-Jacques (2021). Phase 2 study of pembrolizumab (pembro) for locally advanced (LA) or recurrent/metastatic (R/M) cutaneous squamous cell carcinoma (cSCC): KEYNOTE-629. Annual Meeting of the American-Association-for-Cancer-Research (AACR), Philadelphia Pa, Apr 10-May 21, 2021. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. |
|
2021 Conference Publication KEYNOTE-629: Health-related quality of life (HRQoL) with pembrolizumab (pembro) in patients (pts) with locally advanced (LA) or recurrent or metastatic (R/M) cutaneous squamous cell carcinoma (cSCC)Bratland, Ase, Munoz-Couselo, Eva, Mortier, Laurent, Roshdy, Osama, Gonzalez, Rene, Schachter, Jacob, Arance, Ana Maria, Grange, Florent, Meyer, Nicolas, Joshi, Abhishek Jagdish, Billan, Salem, Hughes, Brett Gordon Maxwell, Grob, Jean-Jacques, Ramakrishnan, Karthik, Zhang, Eric (Pingye), Gumuscu, Burak, Swaby, Ramona F. and Gutzmer, Ralf (2021). KEYNOTE-629: Health-related quality of life (HRQoL) with pembrolizumab (pembro) in patients (pts) with locally advanced (LA) or recurrent or metastatic (R/M) cutaneous squamous cell carcinoma (cSCC). Virtual Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Electr Network, Jun 04-08, 2021. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. doi: 10.1200/JCO.2021.39.15_suppl.9546 |
|
2020 Conference Publication Abstract 3384: characterization of the tumor microenvironment and liquid biopsy in head and neck and non-small cell lung cancerKulasinghe, Arutha, Kapeleris, Joanna, Kenny, Liz, Hughes, Brett, Warkiani, Majid, Vela, Ian, Thiery, Jean-Paul, O'Byrne, Ken and Punyadeera, Chamindie (2020). Abstract 3384: characterization of the tumor microenvironment and liquid biopsy in head and neck and non-small cell lung cancer. AACR Annual Meeting 2020, Philadelphia, PA USA, 27-28 April 2020 and 22-24 June 2020. Philadelphia, PA USA: American Association for Cancer Research. doi: 10.1158/1538-7445.am2020-3384 |
|
2020 Conference Publication Limited benefit of adjuvant chemotherapy in resected Epidermal Growth Factor Receptor (EGFR) positive non-small cell lung cancer (NSCLC)O'Leary, Connor, Fletcher, James, Yuile, Alexander, Xu, Wen, Ladwa, Rahul, McGrath, Margaret, Pavlakis, Nick, Hughes, Brett, McCaffery, Elizabeth and O'Byrne, Kenneth (2020). Limited benefit of adjuvant chemotherapy in resected Epidermal Growth Factor Receptor (EGFR) positive non-small cell lung cancer (NSCLC). Medical Oncology Group of Australia Annual Scientific Meeting, Virtual, Australia, 14-21 August 2020. Chichester, West Sussex, United Kingdom: Wiley-Blackwell. |
|
2019 Conference Publication Impact of prior lines of systemic therapy (PST) on the efficacy of cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with advanced cutaneous squamous cell carcinoma (CSCC)Rischin, D., Khushalani, N. I., Schmults, C. D., Guminski, A., Chang, A. L. S., Lewis, K. D., Lim, A. M., Hernandez-Aya, L., Hughes, B. G. M., Schadendorf, D., Hauschild, A., Stankevich, E., Booth, J., Li, S., Chen, Z., Desai, J., Lowy, I., Fury, M. G. and Migden, M. R. (2019). Impact of prior lines of systemic therapy (PST) on the efficacy of cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with advanced cutaneous squamous cell carcinoma (CSCC). Immuno-Oncology Congress of the European-Society-for-Medical-Oncology (ESMO), Geneva Switzerland, Dec 11-14, 2019. OXFORD: OXFORD UNIV PRESS. |
|
2019 Conference Publication Phase II study of 2 dosing regimens of cemiplimab, a human monoclonal anti-PD-1, in metastatic cutaneous squamous cell carcinoma (mCSCC)Rischin, D., Lim, A. M., Schmults, C. D., Khushalani, N. I., Hughes, B. G., Schadendorf, D., Dunn, L. A., Chang, A. L. S., Hauschild, A., Ulrich, C., Eigentler, T., Migden, M. R., Pavlick, A. C., Geiger, J., Stankevich, E., Li, S., Lowy, I., Fury, M. G. and Guminski, A. (2019). Phase II study of 2 dosing regimens of cemiplimab, a human monoclonal anti-PD-1, in metastatic cutaneous squamous cell carcinoma (mCSCC). 44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona, Spain, 27 September - 1 October 2019. Oxford, United Kingdom: Oxford University Press. |
|
2019 Conference Publication Pembrolizumab for recurrent/metastatic cutaneous squamous cell carcinoma (cSCC): Efficacy and safety results from the phase II KEYNOTE-629 studyGrob, J. J., Gonzalez Mendoza, R., Basset-Seguin, N., Vornicova, O., Schachter, J., Joshi, A., Meyer, N., Grange, F., Piulats, J. M., Bauman, J., Zhang, P., Gumuscu, B., Swaby, R. F. and Hughes, B. G. M. (2019). Pembrolizumab for recurrent/metastatic cutaneous squamous cell carcinoma (cSCC): Efficacy and safety results from the phase II KEYNOTE-629 study. 44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona Spain, Sep 27-Oct 01, 2019. OXFORD: OXFORD UNIV PRESS. |
|
2019 Conference Publication KEYNOTE-629: Phase II study of pembrolizumab for recurrent/metastatic or locally advanced unresectable cutaneous squamous cell carcinomaGrob, Jean-Jacques, Gonzalez Mendoza, Rene, Basset-Seguin, Nicole, Schachter, Jacob, Vornicova, Olga, Bauman, Jessica, Grange, Florent, Meyer, Nicolas, Piulats, Josep, Zhang, Pingye (Eric), Gumuscu, Burak, Swaby, Ramona and Hughes, Brett G. M. (2019). KEYNOTE-629: Phase II study of pembrolizumab for recurrent/metastatic or locally advanced unresectable cutaneous squamous cell carcinoma. AACR Annual Meeting on Bioinformatics, Convergence Science, and Systems Biology, Atlanta Ga, Mar 29-Apr 03, 2019. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. doi: 10.1158/1538-7445.AM2019-CT170 |
|
2019 Conference Publication Preoperative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC) (POPCORN)Ahern, Elizabeth Stephanie, Cubitt, Annette, Ballard, Emma, Teng, Michele W.L., Dougall, William C., Smyth, Mark J. and Hughes, Brett Gordon Maxwell (2019). Preoperative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC) (POPCORN). 2019 ASCO-SITC Clinical Immuno-Oncology Symposium, San Francisco, CA United States, 28 February — 2 March 2019. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2019.37.8_suppl.tps129 |
|
2019 Conference Publication Evaluating the prognostic significance of significant weight loss in patients with stage III non-small cell lung cancer (NSCLC) undergoing definitive chemoradiation (CRT) after FOG-PET stagingSenko, Clare, Moore, Julie, Hay, Karen, Lwin, Zarnie, Pratt, Gary, Fong, Kwun and Hughes, Brett Gordon Maxwell (2019). Evaluating the prognostic significance of significant weight loss in patients with stage III non-small cell lung cancer (NSCLC) undergoing definitive chemoradiation (CRT) after FOG-PET staging. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, United States, 31 May - 4 June 2019. Alexandria, VA, United States: American Society of Clinical Oncology. |
